According to the latest report by IMARC Group, titled “China Genetic Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, the China genetic testing market reached a value of US$
3.1 Billion in 2021. Genetic tests identify the changes occurring in the genes, proteins or chromosomes of an individual. They help in determining the chances of a person passing on a genetic disorder to the next generation as well as their vulnerability to a suspected genetic disease. The genetic testing market in China has witnessed rapid development since the establishment of the first genomics company in 1999. The demand for genetic testing services in the country is being driven by factors like aging population, expanding middle class and investments in the healthcare sector. The industry has also attracted international investors owing to rising demand for noninvasive prenatal testing and growing research in the fields of reproductive and oncology health.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
In an effort to expand its domestic biotechnology sector, the Chinese Government has taken steps in the favor of genetic science development. It identified genomics as a strategic field for the country’s social and economic development in its 14th Five-Year Plan. The Government also plans to document the genetic makeup of people from nine different minority groups, in an attempt to decode hereditary information within their genes. Apart from this, the market for direct-to-consumer DNA testing has also experienced massive growth driven by rising priority of personal health and wellness among consumers. This trend has further been supported by technological advancements which have reduced the cost of DNA sequencing services. However, there is a lack of specifically-designed educational programs for training medical genetic professionals in China. Despite this hindrance, the China genetic testing market value is expected to reach US$
8.0 Billion by 2027, at a projected CAGR of
17% during 2022-2027.
- On the basis of test type, the market is segmented into prenatal testing, newborn testing, diagnostic testing, carrier testing, predictive or presymptomatic testing and others. Amongst these, prenatal testing is the most popular segment.
- Based on diseases, the market has been segregated into cancer, Down syndrome, thalassemia and others. At present, cancer remains the leading cause of death in China owing to which genetic tests are gaining popularity as these tests help the doctors in identifying suitable medication for patients.
- The market has been categorized on the basis of technologies into cytogenetic, biochemical and molecular. Amongst these, biochemical is the most common technology used for conducting genetic tests in China.
- There are several service providers available in China for genetic testing such as hospital-based laboratories, independent laboratories and specialty clinics. Hospital-based laboratories exhibit a clear dominance in the market.
- The report has analyzed the China genetic testing market according to different testing samples which include blood, saliva, hair and others. Amongst these, blood samples hold the majority of the market share.
- The competitive landscape of the market has also been examined with some of the key players being BGI, Berry Genomics Co. ltd., Daan Gene Co. Ltd, WuXi NextCODE, Annoroad Gene Technology Co. Ltd., WuXi PharmaTech.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Phone No: (D) +91 120 433 0800 | www.imarcgroup.com
Americas :- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331